Traumatic Brain Injury – Epidemiology – Mature Markets
DRG Epidemiology's coverage of traumatic brain injury (TBI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the number of ED admissions and hospitalizations for TBI in each country as well as annualized events projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.
DRG Epidemiology's TBI forecast will answer the following questions:
- What is the incidence of TBI ED and hospital admissions in the mature markets, and how does it vary by country?
- In the population diagnosed with TBI, what is the severity of these events?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of TBI over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the number of ED and hospital admissions for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following TBI subpopulations:
- Severity status.
Note: Coverage may vary by country.
Table of contents
- Traumatic Brain Injury - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Emergency Department and Hospital Admission Rates for Traumatic Brain Injury per 1,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Emergency Department and Hospital Admissions for Traumatic Brain Injury over the Next 20 Years
- Analysis of Traumatic Brain Injury Admissions in 2021 by Severity
- Epidemiology Data
- Methods
- Diagnosed Events of Traumatic Brain Injury
- Severity of Diagnosed Events of Traumatic Brain Injury
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Traumatic Brain Injury
- Studies Excluded from the Analysis of Traumatic Brain Injury
- Risk/Protective Factors
- Risk/Protective Factors for Traumatic Brain Injury
- Bibliography
- Glossary
- Literature Review
- Introduction
Sunali Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.